If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine injection)100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
When transitioning pediatric patients, aged 6 to 15 years with type 1 diabetes mellitus, to Basaglar, the dosage recommendation is the same as that described for adults. As in adults, the dosage of Basaglar must be individualized in these pediatric patients based on
The efficacy and safety of Basaglar have not been established for the treatment of pediatric patients
1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Date of Last Review: April 14, 2021